ImageneBio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 4.1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 46.54M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Details
| Name | ImageneBio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 18 |
| Founded | 2019 |
| Ceo | Kristin Yarema |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US45175G2075 |
| Cusip | 45175G207 |
| Cik | 0001835579 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Kristin Yarema Ph.D. | Chief Executive Officer and Director |
| Yanina Grant-Huerta | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Dr. Kurinji Pandiyan Ph.D. | Chief Strategy and Operations Officer |
| Renuka Sivendran Ph.D. | Chief Technical Officer |
| Matt Robbins J.D. | General Counsel |
Contact
| Address | 12526 High Bluff Drive, Suite 345, San Diego, California 92130, United States |
| Phone | 858 345 6265 |
| Website | https://www.inmagenebio.com |